Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.

This paper reviews the generalized application of the linear quadratic (LQ) model of radiobiological effect to targeted radiotherapy. Special attention is given to formulations for normal tissue responses and these are applied, in particular, to the kidney. Because it is derived from self-consistent bio-physical principles, the LQ model currently remains the standard formalism for assessing biological responses for the whole range of radiotherapy treatments. A central feature of the model is the derivation of biologically effective doses (BEDs), which may be used to quantify the impact of a treatment on both tumors and normal tissues. BEDs are routinely derived for conventional external-beam treatments. The likely limits of targeted radiotherapy may, thus, be assessed by comparing the expected normal-tissue BEDs for such treatments with those known to be just tolerable in conventional therapy. The main parameters required in the model are defined, and data are provided which demonstrate the tentative link between targeted radiotherapy doses and those used in conventional radiotherapy. The extension of the LQ method to targeted radiotherapy involves using parameters for which the numerical values may not be accurately known at present. This places a restriction on the overall predictive accuracy of the model and the necessary caveats are, therefore, outlined.

[1]  S. Dische,et al.  The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART). , 1990, International journal of radiation oncology, biology, physics.

[2]  J. Fowler,et al.  A new incomplete-repair model based on a 'reciprocal-time' pattern of sublethal damage repair. , 1999, Acta oncologica.

[3]  S. Goddu,et al.  Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  G. Barendsen,et al.  Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. , 1982, International journal of radiation oncology, biology, physics.

[5]  Applied Radiobiology and Bioeffect Planning , 2001 .

[6]  M. Konijnenberg,et al.  Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? , 2003, Cancer biotherapy & radiopharmaceuticals.

[7]  P. Lambin,et al.  Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate? , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  M. Williams,et al.  Basic clinical radiobiology , 1994, British Journal of Cancer.

[9]  D A Morgan,et al.  The role of biologically effective dose (BED) in clinical oncology. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  P. Canney,et al.  Derivation and application of equations describing the effects of fractionated protracted irradiation, based on multiple and incomplete repair processes. Part 2. Analysis of mouse lung data. , 1993, International journal of radiation biology.

[11]  J. Hendry,et al.  Two components of repair in irradiated kidney colony forming cells. , 1994, International journal of radiation biology.

[12]  R. Dale,et al.  A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd , 2001, Physics in medicine and biology.

[13]  J. Fowler The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[14]  Ethaar El-Emir,et al.  The Nonuniformity of Antibody Distribution in the Kidney and its Influence on Dosimetry , 2003, Radiation research.

[15]  S. Goddu,et al.  Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. , 1998, Medical physics.

[16]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[17]  George Sgouros,et al.  MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  R G Dale,et al.  Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.

[19]  H D Thames,et al.  An 'incomplete-repair' model for survival after fractionated and continuous irradiations. , 1985, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[20]  C. Armpilia,et al.  The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. , 2003, International journal of radiation oncology, biology, physics.